Short Interest in Dyadic International, Inc. (NASDAQ:DYAI) Increases By 50.2%

Dyadic International, Inc. (NASDAQ:DYAI) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 151,600 shares, an increase of 50.2% from the April 30th total of 100,900 shares. Based on an average daily trading volume, of 41,800 shares, the days-to-cover ratio is currently 3.6 days. Approximately 0.7% of the shares of the stock are short sold.

Hedge Funds Weigh In On Dyadic International

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Callan Capital LLC increased its holdings in Dyadic International by 86.8% in the 1st quarter. Callan Capital LLC now owns 50,759 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 23,585 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Dyadic International in the fourth quarter valued at about $28,000. Bank of America Corp DE increased its stake in shares of Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the period. Jane Street Group LLC acquired a new stake in shares of Dyadic International in the fourth quarter valued at about $45,000. Finally, Two Sigma Securities LLC acquired a new stake in shares of Dyadic International in the fourth quarter valued at about $25,000. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Price Performance

Shares of DYAI stock traded up $0.02 on Friday, hitting $1.05. 13,558 shares of the company’s stock were exchanged, compared to its average volume of 66,056. Dyadic International has a 12 month low of $0.93 and a 12 month high of $2.67. The company has a 50 day moving average of $1.17 and a 200 day moving average of $1.43. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.15. The stock has a market cap of $31.60 million, a P/E ratio of -4.57 and a beta of 1.01.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter. Dyadic International had a negative return on equity of 149.16% and a negative net margin of 188.09%. The firm had revenue of $0.39 million during the quarter. On average, equities research analysts predict that Dyadic International will post -0.18 EPS for the current year.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.